Digestive Diseases and Sciences

, Volume 52, Issue 2, pp 570–578

Clinical Implications of Hepatic Steatosis in Patients with Chronic Hepatitis C: A Multicenter Study of U.S. Veterans

  • Ke-Qin Hu
  • Sue L. Currie
  • Hui Shen
  • Ramsey C. Cheung
  • Samuel B. Ho
  • Edmund J. Bini
  • John D. McCracken
  • Tim Morgan
  • Norbert Bräu
  • Warren N. Schmidt
  • Lennox Jeffers
  • Teresa L. Wright
  • for the VA HCV-001 Study Grouptitle
Original Paper

DOI: 10.1007/s10620-006-9418-4

Cite this article as:
Hu, K., Currie, S.L., Shen, H. et al. Dig Dis Sci (2007) 52: 570. doi:10.1007/s10620-006-9418-4
  • 77 Views

Abstract

Studies have indicated a high prevalence of hepatic steatosis in patients with chronic hepatitis C (CHC). To address the impact of steatosis on the clinical course of CHC and treatment response requires large multicenter studies. The present study analyzed hepatitis C virus (HCV)-infected veterans enrolled in a U.S. Veteran Administration multicenter study of the epidemiology and response to interferon α-2b and ribavirin treatment. Of the 357 patients, 97.1% were males, with a mean age of 48.7±6.4 years, and 184 (51.5%) had hepatic steatosis. The mean body mass index (BMI) was 29.3±5.2 kg/m2, including 37.1% who were obese (BMI, ≥30 kg/m2). Stage III–IV fibrosis was present in 111 of 334 (33.3%) of the patients. After adjusting for age, race, and history of alcohol use in the past 12 months, only stage III–IV fibrosis was independently and significantly associated with hepatic steatosis (P=0.03). There was a trend of association between obesity and steatosis independent of the other factors. Only HCV genotype was independently associated with a sustained virological response (SVR) to interferon α-2b and ribavirin treatment after adjusting for age, alcohol use, steatosis, BMI, stage III–IV fibrosis, serum AFP, and HCV load. In conclusion, analyses of our multicenter trial data demonstrated that the prevalence of hepatic steatosis is 51.5% in HCV-infected U.S. veterans. We found that steatosis is independently associated with stage III–IV fibrosis. However, only HCV genotype, and not steatosis, obesity, or stage III–IV fibrosis, was associated with SVR to interferon α-2b and ribavirin treatment.

Keywords

Hepatitis C virusChronic hepatitis CHepatic steatosisObesityBody mass indexHepatic fibrosis

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • Ke-Qin Hu
    • 1
    • 2
  • Sue L. Currie
    • 3
  • Hui Shen
    • 3
  • Ramsey C. Cheung
    • 4
  • Samuel B. Ho
    • 5
  • Edmund J. Bini
    • 6
  • John D. McCracken
    • 7
    • 8
  • Tim Morgan
    • 9
  • Norbert Bräu
    • 10
  • Warren N. Schmidt
    • 11
  • Lennox Jeffers
    • 12
  • Teresa L. Wright
    • 3
  • for the VA HCV-001 Study Grouptitle
  1. 1.Contributed to this study when he was the staff hepatologist at Loma Linda VA Medical CenterLoma LindaUSA
  2. 2.Division of Gastroenterology/HepatologyUniversity of California, Irvine, 101 The City DriveOrangeUSA
  3. 3.Veteran Affairs Medical CenterSan FranciscoUSA
  4. 4.Veteran Affairs Medical CenterPalo AltoUSA
  5. 5.Veteran Affairs Medical CenterMinneapolisUSA
  6. 6.Veteran Affairs Medical CenterNew YorkUSA
  7. 7.Contributed to this study when he was the staff Gastroenterologist at Loma Linda VA Medical CenterLoma LindaUSA
  8. 8.Kaiser Permanente 2025 Morse Avenue SacramentoSacramentoUSA
  9. 9.Veteran Affairs Medical CenterLong BeachUSA
  10. 10.Veteran Affairs Medical CenterThe BronxUSA
  11. 11.Veteran Affairs Medical CenterIowa CityUSA
  12. 12.Veteran Affairs Medical CenterMiamiUSA